$BWXT

Jim Cramer Favors BWX Technologies (BWXT) Over Cameco (CCJ)

Jim Cramer prefers BWX Technologies (BWXT) over Cameco (CCJ) for nuclear power investment, citing BWXT's stronger recent performance and Cameco's longer-term potential. BWXT reported Q2 revenue of $901.6M, up 18% YoY, and raised 2026 guidance. Cameco's Q2 uranium segment revenue fell to C$252M from C$352M YoY, but maintained production outlook. Both companies saw increased hedge fund interest.

Original reporting
Published Sep 15, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 10:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jim Cramer Favors BWX Technologies (BWXT) Over Cameco (CCJ) — source image
Decision brief

The 30-second read

$BWXTBullishMed
01

Why it matters

The commentary provides fresh guidance and contract details that were not previously reported, offering actionable insight for traders.

02

Market read

Both stocks are directly impacted by the new earnings data and contract announcements, influencing the nuclear and defense investment themes.

03

What to watch

Potential supply‑chain constraints in uranium mining could affect Cameco's longer‑term outlook.

Relevance 7/10Novelty 6/10Timing: post‑earnings commentary

Background

Jim Cramer compared BWXT and Cameco, noting BWXT's stronger near‑term momentum versus Cameco's longer‑term nuclear play.

Company-level read

Ticker impact

$BWXTBullishMedium confidence
Context

BWXT raised its 2026 adjusted EBITDA guidance to $662M‑$672M and announced a $4M NNSA contract and the Janus program selection.

Expected impact

Potential upside of 5‑8% on near‑term trading.

Evidence & confidence

Guidance lift and contract wins signal stronger revenue growth and defense exposure.

$CCJBearishMedium confidence
Context

Cameco reported Q2 adjusted EBITDA of C$391M, down in uranium segment, and reaffirmed 2026 production outlook.

Expected impact

Potential downside of 3‑5% on short‑term trading.

Evidence & confidence

Weaker uranium earnings and timing risk may weigh on investor sentiment.

Market effects

Highlights growing defense and nuclear infrastructure demand, benefiting the broader industrial and energy sectors.

U.S. defense contractors may see increased interest; Canadian uranium producers face timing risk.

Signals continued policy support for nuclear power worldwide.

Counterpoint

Investors may view BWXT's government contract exposure as a risk if defense spending tightens.

Key entities

  • BWX Technologies, Inc.

    U.S. supplier of nuclear components and services.

  • Cameco Corporation

    Canadian uranium producer and nuclear‑fuel‑cycle company.

Related articles

$BWXTHigh

BWXT Looks 4.3% Undervalued on GF Value™

Guggenheim initiated coverage on BWX Technologies (BWXT) with a Buy rating and $192 price target, citing its strategic nuclear sector position. GF Value™ indicates BWXT is 4.3% undervalued at $148.53 vs. $155.28 intrinsic value. The company has a GF Score™ of 93/100, strong growth, and profitability but faces insider selling and premium valuation concerns.

$BWXTMed

Bwxt stock hits 52-week low at 146.1 USD

BWX Technologies Inc. (BWXT) stock hit a 52-week low of $145.91, down 40% from its high. Q2 2026 earnings beat estimates at $1.07 EPS, but revenue missed at $901.6M. Sales rose 18% YoY, and the company raised full-year free cash flow guidance to $345M-$360M. BWXT's backlog grew to $8.4B, up 40% YoY. Jefferies initiated coverage with a Buy rating, and Wells Fargo upgraded to Equal Weight.

$BWXTMed

Can BWXT's Canadian Lab Role Strengthen Nuclear Services Growth?

BWX Technologies (BWXT) is expanding its nuclear services through a new Canadian lab management role via a joint venture. The contract began in December 2025, complementing BWXT's broader strategy. The Kinectrics acquisition, completed in May 2025, is key to this expansion. BWXT's commercial revenues grew 62.8% YoY to $853.1M in 2025, with Kinectrics contributing $231M. Analysts expect EPS growth of 18.45% and 10.73% for 2026 and 2027, respectively.

$CCJMed

Jefferies Sees Cameco (CCJ) and BWXT as Winners in the Nuclear Boom

Jefferies initiated coverage of Cameco (CCJ) and BWXT (BWXT) with 'Buy' ratings, setting price targets of $138 and $181 respectively, citing strong long-term prospects in nuclear energy. CCJ, a major uranium producer, and BWXT, a nuclear reactor provider, are positioned to benefit from global and U.S. initiatives to expand nuclear capacity. Both companies face risks, including uranium price volatility for CCJ and execution challenges for BWXT.

$BWXTHighAI 8/10

BWX Technologies Already Builds Reactors for the Navy. Why Is It Still the Cheapest Nuclear Stock?

BWX Technologies (NYSE: BWXT) is the lowest-valued nuclear stock despite its monopoly in supplying nuclear reactors and fuel to the U.S. Navy. Its Q2 revenue rose 18% YoY to $901.6M, with EPS up 5% to $1.07. The company has an $8.6B backlog and raised its yearly revenue guidance to $3.8B. BWX also expanded into commercial markets, with Q2 commercial revenue up 72% YoY to $303M.

$BWXTMed

Expansion of Commercial Operations in Focus for BWX Technologies (BWXT)

Wells Fargo upgraded BWX Technologies (BWXT) to Equal Weight, lowering its target price to $170. The company reported Q2 2026 revenue of $901.6M, up from $764M last year, with adjusted EPS of $1.07. BWXT raised its full-year revenue guidance to $3.8B and adjusted EPS guidance to $4.70-$4.80. The stock is down 11.89% year-to-date. Management highlighted growth in commercial operations, while analysts noted risks related to revenue mix and leverage.